pirtobrutinib combined with BEAM

Phase 2

RRuijin Hospital

pirtobrutinib combined with BEAM is one of 19 therapeutic programs targeting DLBCL. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

DLBCLNot yet recruiting

DLBCLPhase 2

Not yet recruiting

Competition

Competitive Landscape

21 competitors in DLBCL

#DrugCompanyPhaseTrials

Nolvadex

AstraZeneca

Phase 3

1 2

COLUMVI

Roche

Phase 2

3 3

Gemzar

Johnson & Johnson

Phase 2

2 4

Eloxatin

Teva

Phase 2

2 5

Epkinly

Genmab

Phase 2

2 6

Yescarta

Gilead

Phase 2

1 7

Venclexta

AbbVie

Phase 2

1 8

Gazyva

Roche

Phase 2

1 9

Aliqopa

Bayer

Phase 2

1 10

Imbruvica

PPharmacyclics LLC.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Not yet recruiting

DLBCL

NCT07774299

Clinical

Trials by Indication[1]

DLBCL1 trial

A Multicenter, Single-Arm Clinical Study of Pirtobrutinib Combined With Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preconditioning Regimen for ASCT in Relapsed and Refractory DLBCL

Not yet recruiting·RRuijin Hospital·Phase 2·NCT07774299·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for pirtobrutinib combined with BEAM. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for pirtobrutinib combined with BEAM. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ruijin Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: RRuijin Hospital

pirtobrutinib combined with BEAM

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

DLBCL1 trial

References

Drug Info

Quick Facts

Related News